Below are the most recent publications written about "Complement Activation" by people in Profiles.
-
Diurno F, Numis FG, Porta G, Cirillo F, Maddaluno S, Ragozzino A, De Negri P, Di Gennaro C, Pagano A, Allegorico E, Bressy L, Bosso G, Ferrara A, Serra C, Montisci A, D'Amico M, Schiano Lo Morello S, Di Costanzo G, Tucci AG, Marchetti P, Di Vincenzo U, Sorrentino I, Casciotta A, Fusco M, Buonerba C, Berretta M, Ceccarelli M, Nunnari G, Diessa Y, Cicala S, Facchini G. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci. 2020 04; 24(7):4040-4047.
-
Merrill SA, Brodsky RA, Lanzkron SM, Naik R. A case-control analysis of hyperhemolysis syndrome in adults and laboratory correlates of complement involvement. Transfusion. 2019 10; 59(10):3129-3139.
-
Keller CW, Quast I, Dalakas MC, L?nemann JD. IVIG efficacy in CIDP patients is not associated with terminal complement inhibition. J Neuroimmunol. 2019 05 15; 330:23-27.
-
Ali HA, Pavlisko EN, Snyder LD, Frank M, Palmer SM. Complement system in lung transplantation. Clin Transplant. 2018 04; 32(4):e13208.
-
Holinstat M. Complement factors (H) into thrombosis. Blood. 2017 03 02; 129(9):1065-1066.
-
Velickovic I, Dalloul M, Wong KA, Bakare O, Schweis F, Garala M, Alam A, Medranda G, Lekovic J, Shuaib W, Tedjasukmana A, Little P, Hanono D, Wijetilaka R, Weedon J, Lin J, Toledano Rd, Zhang M. Complement factor B activation in patients with preeclampsia. J Reprod Immunol. 2015 Jun; 109:94-100.
-
Dalakas MC. Mechanistic effects of IVIg in neuroinflammatory diseases: conclusions based on clinicopathologic correlations. J Clin Immunol. 2014 Jul; 34 Suppl 1:S120-6.
-
Br?ck W, Popescu B, Lucchinetti CF, Markovic-Plese S, Gold R, Thal DR, Metz I. Neuromyelitis optica lesions may inform multiple sclerosis heterogeneity debate. Ann Neurol. 2012 Sep; 72(3):385-94.
-
Bellone S, Roque D, Cocco E, Gasparrini S, Bortolomai I, Buza N, Abu-Khalaf M, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy. Br J Cancer. 2012 Apr 24; 106(9):1543-50.
-
Mattsson J, Yrlid U, Stensson A, Sch?n K, Karlsson MC, Ravetch JV, Lycke NY. Complement activation and complement receptors on follicular dendritic cells are critical for the function of a targeted adjuvant. J Immunol. 2011 Oct 01; 187(7):3641-52.